Antidepressant studies in Parkinson's disease: A review and meta‐analysis
Identifieur interne : 001609 ( Main/Corpus ); précédent : 001608; suivant : 001610Antidepressant studies in Parkinson's disease: A review and meta‐analysis
Auteurs : Daniel Weintraub ; Knashawn H. Morales ; Paul J. Moberg ; Warren B. Bilker ; Catherine Balderston ; John E. Duda ; Ira R. Katz ; Matthew B. SternSource :
- Movement Disorders [ 0885-3185 ] ; 2005-09.
English descriptors
- KwdEn :
Abstract
The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta‐analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta‐analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20555
Links to Exploration step
ISTEX:610D5153D437DE1BD4291B98BC75F6102D891AA5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antidepressant studies in Parkinson's disease: A review and meta‐analysis</title><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Morales, Knashawn H" sort="Morales, Knashawn H" uniqKey="Morales K" first="Knashawn H." last="Morales">Knashawn H. Morales</name><affiliation><mods:affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Moberg, Paul J" sort="Moberg, Paul J" uniqKey="Moberg P" first="Paul J." last="Moberg">Paul J. Moberg</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Bilker, Warren B" sort="Bilker, Warren B" uniqKey="Bilker W" first="Warren B." last="Bilker">Warren B. Bilker</name><affiliation><mods:affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Balderston, Catherine" sort="Balderston, Catherine" uniqKey="Balderston C" first="Catherine" last="Balderston">Catherine Balderston</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Duda, John E" sort="Duda, John E" uniqKey="Duda J" first="John E." last="Duda">John E. Duda</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Katz, Ira R" sort="Katz, Ira R" uniqKey="Katz I" first="Ira R." last="Katz">Ira R. Katz</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:610D5153D437DE1BD4291B98BC75F6102D891AA5</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20555</idno><idno type="url">https://api.istex.fr/document/610D5153D437DE1BD4291B98BC75F6102D891AA5/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001609</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antidepressant studies in Parkinson's disease: A review and meta‐analysis</title><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Morales, Knashawn H" sort="Morales, Knashawn H" uniqKey="Morales K" first="Knashawn H." last="Morales">Knashawn H. Morales</name><affiliation><mods:affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Moberg, Paul J" sort="Moberg, Paul J" uniqKey="Moberg P" first="Paul J." last="Moberg">Paul J. Moberg</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Bilker, Warren B" sort="Bilker, Warren B" uniqKey="Bilker W" first="Warren B." last="Bilker">Warren B. Bilker</name><affiliation><mods:affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Balderston, Catherine" sort="Balderston, Catherine" uniqKey="Balderston C" first="Catherine" last="Balderston">Catherine Balderston</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Duda, John E" sort="Duda, John E" uniqKey="Duda J" first="John E." last="Duda">John E. Duda</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Katz, Ira R" sort="Katz, Ira R" uniqKey="Katz I" first="Ira R." last="Katz">Ira R. Katz</name><affiliation><mods:affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Stern, Matthew B" sort="Stern, Matthew B" uniqKey="Stern M" first="Matthew B." last="Stern">Matthew B. Stern</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-09">2005-09</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1161">1161</biblScope><biblScope unit="page" to="1169">1169</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">610D5153D437DE1BD4291B98BC75F6102D891AA5</idno><idno type="DOI">10.1002/mds.20555</idno><idno type="ArticleID">MDS20555</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>antidepressive agent</term><term>depression</term><term>effect size</term><term>meta‐analysis</term><term>treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta‐analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta‐analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD. © 2005 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Daniel Weintraub MD</name><affiliations><json:string>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string><json:string>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</json:string><json:string>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Knashawn H. Morales ScD</name><affiliations><json:string>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Paul J. Moberg PhD</name><affiliations><json:string>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string><json:string>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Warren B. Bilker PhD</name><affiliations><json:string>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Catherine Balderston MS</name><affiliations><json:string>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>John E. Duda MD</name><affiliations><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string><json:string>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Ira R. Katz MD, PhD</name><affiliations><json:string>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string><json:string>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Matthew B. Stern MD</name><affiliations><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</json:string><json:string>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>antidepressive agent</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>effect size</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>meta‐analysis</value></json:item></subject><articleId><json:string>MDS20555</json:string></articleId><language><json:string>eng</json:string></language><abstract>The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta‐analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta‐analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD. © 2005 Movement Disorder Society</abstract><qualityIndicators><score>7.664</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>1522</abstractCharCount><pdfWordCount>5491</pdfWordCount><pdfCharCount>36489</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>222</abstractWordCount></qualityIndicators><title>Antidepressant studies in Parkinson's disease: A review and meta‐analysis</title><genre><json:string>article</json:string></genre><host><volume>20</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>9</total><last>1169</last><first>1161</first></pages><issn><json:string>0885-3185</json:string></issn><issue>9</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/mds.20555</json:string></doi><id>610D5153D437DE1BD4291B98BC75F6102D891AA5</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/610D5153D437DE1BD4291B98BC75F6102D891AA5/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/610D5153D437DE1BD4291B98BC75F6102D891AA5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/610D5153D437DE1BD4291B98BC75F6102D891AA5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Antidepressant studies in Parkinson's disease: A review and meta‐analysis</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2005</date></publicationStmt><notesStmt><note>National Institute of Mental Health - No. MH067894;</note><note>Mental Illness Research, Education, and Clinical Center (MIRECC) at the Philadelphia VAMC</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Antidepressant studies in Parkinson's disease: A review and meta‐analysis</title><author><persName><forename type="first">Daniel</forename><surname>Weintraub</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: 3535 Market St., Room 3003, Philadelphia, PA 19104</p></note><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Knashawn H.</forename><surname>Morales</surname></persName><roleName type="degree">ScD</roleName><affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Paul J.</forename><surname>Moberg</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Warren B.</forename><surname>Bilker</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Catherine</forename><surname>Balderston</surname></persName><roleName type="degree">MS</roleName><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">John E.</forename><surname>Duda</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Ira R.</forename><surname>Katz</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Matthew B.</forename><surname>Stern</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-09"></date><biblScope unit="volume">20</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1161">1161</biblScope><biblScope unit="page" to="1169">1169</biblScope></imprint></monogr><idno type="istex">610D5153D437DE1BD4291B98BC75F6102D891AA5</idno><idno type="DOI">10.1002/mds.20555</idno><idno type="ArticleID">MDS20555</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta‐analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta‐analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD. © 2005 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>depression</term></item><item><term>antidepressive agent</term></item><item><term>treatment</term></item><item><term>effect size</term></item><item><term>meta‐analysis</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-01-09">Received</change><change when="2005-01-19">Registration</change><change when="2005-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/610D5153D437DE1BD4291B98BC75F6102D891AA5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="90"><doi origin="wiley" registered="yes">10.1002/mds.v20:9</doi><numberingGroup><numbering type="journalVolume" number="20">20</numbering><numbering type="journalIssue">9</numbering></numberingGroup><coverDate startDate="2005-09">September 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="100" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20555</doi><idGroup><id type="unit" value="MDS20555"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2005 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2004-01-09"></event><event type="manuscriptRevised" date="2005-01-17"></event><event type="manuscriptAccepted" date="2005-01-19"></event><event type="publishedOnlineEarlyUnpaginated" date="2005-06-13"></event><event type="firstOnline" date="2005-06-13"></event><event type="publishedOnlineFinalForm" date="2005-08-22"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText mathml2tex" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1161</numbering><numbering type="pageLast">1169</numbering></numberingGroup><correspondenceTo>3535 Market St., Room 3003, Philadelphia, PA 19104</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20555.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="67"></count><count type="wordTotal" number="6401"></count></countGroup><titleGroup><title type="main" xml:lang="en">Antidepressant studies in Parkinson's disease: A review and meta‐analysis</title><title type="short" xml:lang="en">Meta‐Analysis of Antidepressant Studies in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2 #af3 #af4" corresponding="yes"><personName><givenNames>Daniel</givenNames><familyName>Weintraub</familyName><degrees>MD</degrees></personName><contactDetails><email>weintrau@mail.med.upenn.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Knashawn H.</givenNames><familyName>Morales</familyName><degrees>ScD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af3"><personName><givenNames>Paul J.</givenNames><familyName>Moberg</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Warren B.</givenNames><familyName>Bilker</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Catherine</givenNames><familyName>Balderston</familyName><degrees>MS</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af2 #af3"><personName><givenNames>John E.</givenNames><familyName>Duda</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1 #af4"><personName><givenNames>Ira R.</givenNames><familyName>Katz</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af2 #af3"><personName><givenNames>Matthew B.</givenNames><familyName>Stern</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">depression</keyword><keyword xml:id="kwd3">antidepressive agent</keyword><keyword xml:id="kwd4">treatment</keyword><keyword xml:id="kwd5">effect size</keyword><keyword xml:id="kwd6">meta‐analysis</keyword></keywordGroup><fundingInfo><fundingAgency>National Institute of Mental Health</fundingAgency><fundingNumber>MH067894</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Mental Illness Research, Education, and Clinical Center (MIRECC) at the Philadelphia VAMC</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta‐analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta‐analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD. © 2005 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Antidepressant studies in Parkinson's disease: A review and meta‐analysis</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Meta‐Analysis of Antidepressant Studies in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Antidepressant studies in Parkinson's disease: A review and meta‐analysis</title></titleInfo><name type="personal"><namePart type="given">Daniel</namePart><namePart type="family">Weintraub</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation><description>Correspondence: 3535 Market St., Room 3003, Philadelphia, PA 19104</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Knashawn H.</namePart><namePart type="family">Morales</namePart><namePart type="termsOfAddress">ScD</namePart><affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paul J.</namePart><namePart type="family">Moberg</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Warren B.</namePart><namePart type="family">Bilker</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Catherine</namePart><namePart type="family">Balderston</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John E.</namePart><namePart type="family">Duda</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ira R.</namePart><namePart type="family">Katz</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Mental Illness Research, Education and Clinical Center (MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Matthew B.</namePart><namePart type="family">Stern</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA</affiliation><affiliation>Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-09</dateIssued><dateCaptured encoding="w3cdtf">2004-01-09</dateCaptured><dateValid encoding="w3cdtf">2005-01-19</dateValid><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">67</extent><extent unit="words">6401</extent></physicalDescription><abstract lang="en">The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta‐analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta‐analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD. © 2005 Movement Disorder Society</abstract><note type="funding">National Institute of Mental Health - No. MH067894; </note><note type="funding">Mental Illness Research, Education, and Clinical Center (MIRECC) at the Philadelphia VAMC</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>depression</topic><topic>antidepressive agent</topic><topic>treatment</topic><topic>effect size</topic><topic>meta‐analysis</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1161</start><end>1169</end><total>9</total></extent></part></relatedItem><identifier type="istex">610D5153D437DE1BD4291B98BC75F6102D891AA5</identifier><identifier type="DOI">10.1002/mds.20555</identifier><identifier type="ArticleID">MDS20555</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001609 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001609 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:610D5153D437DE1BD4291B98BC75F6102D891AA5
|texte= Antidepressant studies in Parkinson's disease: A review and meta‐analysis
}}
| This area was generated with Dilib version V0.6.23. |  |